Delivery Order HHSN261201200031I-HHSN26100001

The National Cancer Institute issued a delivery order to Sri International on January 24, 2019, with a ceiling value of $4,446.00 under the PREVENT Preclinical Drug Development Program for a contract orientation and kick-off meeting supporting toxicology and pharmacology testing. The PREVENT program funds preclinical drug development research. Place of performance is Menlo Park, CA. The order period runs from January 25, 2019 through February 24, 2019. The contract is priced on a...

This is a federal contract award to the University of Arizona, doing business as the Arizona Board of Regents, by the National Cancer Institute (NCI) under the Cancer Prevention Agent Development Program 2012-2017. The award has a ceiling value of $2,924,327.60 and is for research and development services related to the core infrastructure support for the NCI's cancer prevention agent development program's early phase clinical research. The contract is a delivery order and does not have a...

The National Cancer Institute issued a delivery order to The Institute For Cancer Research on September 15, 2022, under the PREVENT Preclinical Drug Development Program (PREVENT) IDIQ for preclinical efficacy and intermediate endpoint biomarker studies supporting a nano-drug for colon cancer prevention, with a ceiling value of $1.57 million and ultimate completion date of June 14, 2026. PREVENT is a National Cancer Institute IDIQ structured around three technical pools: Preclinical Efficacy...

The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a delivery order contract to Mayo Clinic, a large non-profit academic medical center, to provide core infrastructure support services. The $658,179.00 contract does not have a set-aside designation and is part of the Cancer Prevention Agent Development Program: Early Phase Clinical Research major program. Mayo Clinic will implement bioanalytical methods, conduct pharmacokinetic...

The Institute For Cancer Research (ICR), a non-profit subsidiary of Temple University, was awarded a $779,932 firm fixed price delivery order against the PREVENT Preclinical Drug Development Program (PREVENT) multiple award master indefinite delivery contract held by the National Cancer Institute. The delivery order, with a completion date of March 2025, will fund continued evaluation of candidate chemopreventive and immunopreventive regimens to support the goals of the PREVENT program in...

The National Cancer Institute issued a delivery order to The Institute For Cancer Research on May 18, 2022, under the PREVENT Preclinical Drug Development Program (PREVENT), a multiple-award indefinite delivery contract with a $1.24 million ceiling for this order. PREVENT is the National Cancer Institute's structured preclinical drug development vehicle supporting candidate chemopreventive and immunopreventive regimens across three technical pools: Preclinical Efficacy and Biomarkers,...

This is a delivery order contract awarded by the National Cancer Institute (NCI), part of the Department of Health and Human Services, to The Institute for Cancer Research, a non-profit research organization and subsidiary of Temple University. The $988,252 firm fixed price contract is for research and development services in the area of biomedical basic research, specifically preclinical efficacy and biomarker analysis to support the NCI's PREVENT Cancer Preclinical Drug Development Program....

The National Cancer Institute issued a delivery order to The University of Texas MD Anderson Cancer Center on September 24, 2015, with a ceiling value of $4.2 million under the Cancer Prevention Agent Development Program 2012-2017 IDIQ for core infrastructure support of early-phase clinical research. Place of performance is Houston, TX. The order is priced on a cost-no-fee basis with an ultimate completion date of September 23, 2019. This delivery order represents Option 2 core infrastructure...

<p>The National Cancer Institute issued a delivery order to Northwestern University on September 24, 2015, under the Cancer Prevention Agent Development Program 2012-2017 IDIQ for core infrastructure support and early-phase clinical research in cancer prevention agent development, with a ceiling value of $3,544,085.97.</p> <p>Place of performance is Chicago, IL. The order carries an ultimate completion date of April 30, 2021 and is priced on a cost-no-fee basis. No set-aside was used.</p>

This federal contract award is a $2,000 delivery order issued against the PREVENT Preclinical Drug Development Program master IDIQ by the National Cancer Institute. The University of Oklahoma Health Sciences Center, as prime contractor, will provide contract orientation and kickoff meeting services from January to February 2019 in Oklahoma City. The purpose of the PREVENT program, managed by the National Institutes of Health, is to support preclinical efficacy testing of novel cancer...